X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
atorvastatin calcium (2042) 2042
heptanoic acids - pharmacology (2022) 2022
humans (1848) 1848
pyrroles - pharmacology (1702) 1702
male (1700) 1700
atorvastatin (1304) 1304
animals (1269) 1269
female (1046) 1046
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (984) 984
pharmacology & pharmacy (956) 956
heptanoic acids - therapeutic use (925) 925
pyrroles - therapeutic use (877) 877
statins (841) 841
middle aged (816) 816
rats (640) 640
aged (525) 525
adult (507) 507
simvastatin (491) 491
cholesterol (483) 483
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (481) 481
heptanoic acids - administration & dosage (463) 463
anticholesteremic agents - pharmacology (456) 456
pyrroles - administration & dosage (442) 442
cardiac & cardiovascular systems (377) 377
dose-response relationship, drug (374) 374
mice (349) 349
pravastatin (346) 346
atherosclerosis (334) 334
peripheral vascular disease (290) 290
antilipemic agents (287) 287
anticholesteremic agents - therapeutic use (286) 286
hypercholesterolemia - drug therapy (274) 274
expression (270) 270
cholesterol - blood (263) 263
inflammation (262) 262
cells, cultured (261) 261
cholesterol, ldl - blood (259) 259
hypercholesterolemia (253) 253
treatment outcome (251) 251
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (242) 242
simvastatin - pharmacology (236) 236
disease models, animal (214) 214
rats, sprague-dawley (213) 213
time factors (213) 213
analysis (210) 210
lipids (209) 209
heptanoic acids - adverse effects (208) 208
rats, wistar (204) 204
pyrroles - adverse effects (201) 201
heptanoic acids - pharmacokinetics (198) 198
biochemistry & molecular biology (197) 197
statin (197) 197
drug interactions (194) 194
coa reductase inhibitors (189) 189
oxidative stress (186) 186
double-blind method (182) 182
drug therapy, combination (182) 182
pyrroles - pharmacokinetics (180) 180
triglycerides - blood (179) 179
lipids - blood (174) 174
hmg-coa reductase (164) 164
risk (164) 164
disease (162) 162
endothelium, vascular - drug effects (162) 162
research (161) 161
therapy (158) 158
simvastatin - therapeutic use (155) 155
nitric-oxide synthase (151) 151
in vitro techniques (148) 148
risk factors (146) 146
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (142) 142
in-vitro (141) 141
prevention (140) 140
hyperlipidemias - drug therapy (139) 139
c-reactive protein (137) 137
coronary-heart-disease (136) 136
apoptosis (134) 134
metabolism (134) 134
activation (128) 128
anticholesteremic agents - administration & dosage (128) 128
rabbits (126) 126
drug therapy (124) 124
medicine & public health (124) 124
pravastatin - pharmacology (124) 124
rosuvastatin calcium (124) 124
cholesterol, hdl - blood (123) 123
rna, messenger - metabolism (123) 123
biphenyl compounds - pharmacology (122) 122
inhibition (121) 121
statin therapy (121) 121
prospective studies (118) 118
cardiovascular (117) 117
hematology (117) 117
liver - metabolism (117) 117
lovastatin (117) 117
heptanoic acids - chemistry (116) 116
apoptosis - drug effects (115) 115
internal medicine (115) 115
pharmacokinetics (115) 115
hypertension (114) 114
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2892) 2892
Japanese (54) 54
Chinese (42) 42
Russian (14) 14
Spanish (13) 13
German (7) 7
Portuguese (6) 6
French (5) 5
Hungarian (4) 4
Polish (3) 3
Italian (2) 2
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Applied biochemistry and biotechnology, ISSN 1559-0291, 2016, Volume 182, Issue 1, pp. 67 - 81
Docosapentaenoic acid/docosahexaenoic acid ratio (DPA/DHA ratio) in Schizochytrium was relatively stable... 
Docosapentaenoic acid / docosahexaenoic acid ratio | Schizochytrium | Docosapentaenoic acid | Docosapentaenoic acid biosynthesis | Polyunsaturated fatty acid synthase | OXIDATION | Docosapentaenoic acid/docosahexaenoic acid ratio | BIOCHEMISTRY & MOLECULAR BIOLOGY | BETA | TRICHOPHYTON-RUBRUM | SYNTHASE INHIBITOR | OIL | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | DOCOSAHEXAENOIC ACID | BIOSYNTHESIS | FATTY-ACID | GROWTH | GENE-EXPRESSION | Propionates - pharmacology | Propionates - metabolism | Transcription, Genetic - drug effects | Heptanoic Acids - metabolism | Fatty Acid Synthases - metabolism | Caproates - pharmacology | Iodoacetamide - pharmacology | Stramenopiles - drug effects | Caprylates - pharmacology | Caprylates - metabolism | Fatty Acids, Unsaturated - biosynthesis | Stramenopiles - growth & development | Butyric Acid - metabolism | Pentanoic Acids - pharmacology | Butyric Acid - pharmacology | Pentanoic Acids - metabolism | Caproates - metabolism | Stramenopiles - genetics | Docosahexaenoic Acids - biosynthesis | Fatty Acid Synthases - genetics | Stramenopiles - enzymology | Heptanoic Acids - pharmacology | Fatty Acids - biosynthesis | Unsaturated fatty acids | Synthesis | Laws, regulations and rules | Analysis | Saturated fatty acids | Fatty acids | Omega-3 fatty acids | Transcription | Incubation | Polyunsaturated fatty acids | Propionic acid | Lipids | Oxidation | Docosahexaenoic acid | Hexanoic acid | Octanoic acid | Butyric acid
Journal Article
Pharmacological research, ISSN 1043-6618, 09/2011, Volume 64, Issue 3, pp. 180 - 186
Statins, long known to be beneficial in conditions where dyslipidemia occurs by lowering serum cholesterol levels, also have been proposed for use in... 
Alzheimer disease | Pleiotropic functions | Statins | Statins as Janus molecules | OXIDATIVE STRESS | COA REDUCTASE INHIBITORS | CLINICAL-TRIAL COHORT | DRUG-INTERACTIONS | NITRIC-OXIDE SYNTHASE | MILD COGNITIVE IMPAIRMENT | CELL-DEATH | COENZYME Q | AMYLOID-BETA | PHARMACOLOGY & PHARMACY | AUTOIMMUNE-DISEASE | Fatty Acids, Monounsaturated - pharmacology | Lovastatin - pharmacology | Heptanoic Acids - therapeutic use | Humans | Heptanoic Acids - adverse effects | Neurodegenerative Diseases - drug therapy | Quinolines - pharmacology | Fluorobenzenes - pharmacology | Fatty Acids, Monounsaturated - therapeutic use | Fatty Acids, Monounsaturated - adverse effects | Pyrroles - adverse effects | Indoles - pharmacology | Pyrroles - therapeutic use | Heptanoic Acids - pharmacology | Lovastatin - therapeutic use | Lovastatin - adverse effects | Alzheimer Disease - drug therapy | Rosuvastatin Calcium | Pyrimidines - pharmacology | Cholesterol - metabolism | Sulfonamides - pharmacology | Atorvastatin Calcium | Pyrroles - pharmacology | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Indoles - adverse effects | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Indoles - therapeutic use | Fluorobenzenes - adverse effects | Quinolines - therapeutic use | Fluorobenzenes - therapeutic use | Quinolines - adverse effects | Alzheimer's disease | Neuroprotection | Neurotoxicity | Neurodegenerative diseases | statins | Dyslipidemia | Clinical trials | Age | Cholesterol | Index Medicus
Journal Article
Xenobiotica, ISSN 0049-8254, 6/2013, Volume 43, Issue 6, pp. 498 - 508
1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and... 
P-glycoprotein | BCRP | transporters | Cytochrome P450 | OATP | dyslipidemia | diabetes | pharmacogenetics | Pharmacogenetics | Dyslipidemia | Transporters | Diabetes | POLYMORPHISM MARKEDLY AFFECTS | SLCO1B1 POLYMORPHISM | ATORVASTATIN | INHIBITION | PHARMACOKINETICS | FLUVASTATIN | PHARMACOLOGY & PHARMACY | TOXICOLOGY | SIMVASTATIN | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Simvastatin - adverse effects | Pyrimidines - blood | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Male | Heptanoic Acids - adverse effects | Simvastatin - pharmacology | Fluorobenzenes - pharmacology | Young Adult | Drug Interactions | Piperidines - pharmacology | Oxadiazoles - pharmacology | Madin Darby Canine Kidney Cells | Pyrroles - adverse effects | Oxadiazoles - pharmacokinetics | Heptanoic Acids - pharmacology | Mesylates - blood | Troleandomycin - adverse effects | Rosuvastatin Calcium | Mesylates - adverse effects | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Simvastatin - analogs & derivatives | Sulfonamides - pharmacokinetics | Oxadiazoles - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Cytochrome P-450 CYP3A - metabolism | Adolescent | Atorvastatin | Pyrimidines - pharmacokinetics | Oxadiazoles - blood | Demography | Heptanoic Acids - pharmacokinetics | Mesylates - pharmacokinetics | Simvastatin - blood | Piperidines - blood | Troleandomycin - pharmacokinetics | Dose-Response Relationship, Drug | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | Reference Standards | Adult | Female | Piperidines - pharmacokinetics | Troleandomycin - pharmacology | Fluorobenzenes - blood | Pyrroles - blood | Simvastatin - pharmacokinetics | Pyrroles - pharmacology | Animals | Cytochrome P-450 CYP3A Inhibitors | Mesylates - pharmacology | Piperidines - adverse effects | Dogs | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Heptanoic Acids - blood
Journal Article
PloS one, ISSN 1932-6203, 2011, Volume 6, Issue 7, p. e21237
The Plasmodium falciparum lactate dehydrogenase enzyme (PfLDH) has been considered as a potential molecular target for antimalarials due to this parasite's... 
DRUG-SENSITIVITY | PARASITES | IN-VITRO | QUINOLINE ANTIMALARIALS | NATURAL-PRODUCTS | BIOLOGY | RESISTANCE | MALARIA | CHLOROQUINE | MOLECULAR DOCKING | CULTURE | L-Lactate Dehydrogenase - metabolism | Plasmodium falciparum - enzymology | Triazoles - chemistry | Heptanoic Acids - therapeutic use | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - chemistry | Plasmodium falciparum - drug effects | Itraconazole - pharmacology | Pyrroles - therapeutic use | Heptanoic Acids - pharmacology | Triazoles - therapeutic use | Catalytic Domain | Enzyme-Linked Immunosorbent Assay | Cells, Cultured | Antimalarials - therapeutic use | Itraconazole - chemistry | Antimalarials - pharmacology | Itraconazole - therapeutic use | Triazoles - pharmacology | Atorvastatin Calcium | Pyrroles - pharmacology | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Heptanoic Acids - chemistry | Antimalarials - chemistry | Pyrroles - chemistry | Mice | Malaria - drug therapy | L-Lactate Dehydrogenase - antagonists & inhibitors | Plasmodium falciparum | Malaria | Analysis | Force and energy | Antimalarials | B cells | Itraconazole | Drugs | Dehydrogenases | Laboratories | Chloroquine | Erythrocytes | Parasites | Dehydrogenase | Drug resistance | Molecular docking | Proteins | Analogs | Toxicology | Histidine | NADH | Parasitic diseases | Parasitemia | Active control | Vector-borne diseases | Enzymes | Antigens | Polymerization | Lactate dehydrogenase | Medical screening | L-Lactate dehydrogenase | Chemotherapy | Antimalarial activity | Inhibitors | Blood parasites | Natural products | Antimalarial agents | Computer applications | Nicotinamide adenine dinucleotide | Glycolysis | Atorvastatin | Lactic acid | Posaconazole
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2014, Volume 111, Issue 46, pp. 16592 - 16597
Insect repellents are important prophylactic tools for travelers and populations living in endemic areas of malaria, dengue, encephalitis, and other... 
Insect antennae | Receptors | Double stranded RNA | Insect vectors | Female animals | Acetates | Mosquitos | Heptanoic acids | Oocytes | Odorant receptors | ELICIT | MULTIDISCIPLINARY SCIENCES | TERMS | picaridin | DROSOPHILA | Culex quinquefasciatus | RESPONSES | INSECT REPELLENTS | IR 3535 | IONOTROPIC GLUTAMATE RECEPTORS | CHEMICALS | DESIGNATION | ATTRACTANT | odorant receptor | southern house mosquito | Receptors, Ionotropic Glutamate - physiology | Smell - genetics | Receptors, Odorant - biosynthesis | Receptors, Ionotropic Glutamate - genetics | Electrophysiology | Molecular Sequence Data | Recombinant Fusion Proteins - metabolism | Smell - physiology | Piperidines - pharmacology | RNA Interference | Aldehydes - pharmacology | beta-Alanine - pharmacology | Cloning, Molecular | Culex - drug effects | Receptors, Odorant - physiology | Female | Transcription, Genetic | beta-Alanine - analogs & derivatives | Arthropod Antennae - physiology | Avoidance Learning | Insect Repellents - pharmacology | Xenopus laevis | Culex - physiology | Cyclopentanes - pharmacology | DEET - pharmacology | Feeding Behavior - physiology | Feeding Behavior - drug effects | Menthol - analogs & derivatives | Animals | Menthol - pharmacology | Oxylipins - pharmacology | Receptors, Odorant - genetics | Acetates - pharmacology | Models, Neurological | Receptors, Odorant - drug effects | Insecticides | Health aspects | Mosquitoes | Biological Sciences
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2005, Volume 352, Issue 1, pp. 20 - 28
Statin therapy lowers not only low-density lipoprotein (LDL) cholesterol levels, but also levels of C-reactive protein (CRP), a marker of inflammation. This... 
MEDICINE, GENERAL & INTERNAL | DENSITY-LIPOPROTEIN CHOLESTEROL | INFLAMMATION | CARDIOVASCULAR-DISEASE | MARKERS | RISK | ACUTE CORONARY SYNDROMES | PRAVASTATIN | PRIMARY PREVENTION | PREDICTION | ATORVASTATIN | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Myocardial Infarction - blood | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Male | Secondary Prevention | Coronary Disease - mortality | Incidence | C-Reactive Protein - metabolism | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Cholesterol, LDL - blood | Female | C-Reactive Protein - drug effects | Pyrroles - therapeutic use | Pravastatin - therapeutic use | Heptanoic Acids - pharmacology | Pravastatin - pharmacology | Coronary Disease - blood | Risk Factors | Proportional Hazards Models | Cholesterol, LDL - drug effects | Fluoroquinolones - therapeutic use | Biomarkers - blood | Atorvastatin Calcium | Coronary Disease - prevention & control | Pyrroles - pharmacology | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Myocardial Infarction - drug therapy | Pravastatin - administration & dosage | Anticholesteremic Agents - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Myocardial Infarction - prevention & control | Anticholesteremic Agents - pharmacology | Cardiovascular disease | Heart attacks | Cholesterol | Statins
Journal Article
BMC biotechnology, ISSN 1472-6750, 2013, Volume 13, Issue 1, pp. 68 - 68
Journal Article
Journal Article
Journal of cellular physiology, ISSN 0021-9541, 09/2011, Volume 226, Issue 9, pp. 2316 - 2328
Journal Article
Journal Article
Epilepsia (Copenhagen), ISSN 0013-9580, 2011, Volume 52, Issue 11, pp. 2094 - 2104
.... Increasing evidence indicates that statins, particularly atorvastatin, are neuroprotective in several conditions, including stroke, cerebral ischemia, traumatic brain injury, and excitotoxic amino acid exposure... 
Statin | Rat | EEG | Epilepsy | Cholesterol | Blood–brain barrier | Blood-brain barrier | OXIDATIVE STRESS | HMG-COA REDUCTASE | BLOOD-BRAIN-BARRIER | STATINS | CLINICAL NEUROLOGY | QUINOLINIC ACID | HIPPOCAMPAL CELL-DEATH | INDUCED EXCITOTOXICITY | CORTICAL-NEURONS | MICE | INHIBITORS | Rats, Wistar | Cholesterol - blood | Seizures - drug therapy | Anticonvulsants - administration & dosage | Male | Electroencephalography | Simvastatin - pharmacology | Anticonvulsants - pharmacology | Seizures - chemically induced | Anticonvulsants - analysis | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Heptanoic Acids - analysis | Heptanoic Acids - pharmacology | Pentylenetetrazole - pharmacology | Cerebral Cortex - chemistry | Anticonvulsants - blood | Simvastatin - administration & dosage | Pyrroles - analysis | Rats | Pyrroles - blood | Blood-Brain Barrier - metabolism | Atorvastatin Calcium | Pyrroles - pharmacology | Animals | Convulsants - pharmacology | Heptanoic Acids - blood | Enzymes | Brain | Thiols | Simvastatin | Amino acids | Liquid chromatography | Permeability | Antilipemic agents | Analysis | Fluorescein | Physiological aspects | Seizures (Medicine) | Mass spectrometry | Injuries | Plasma | Drug therapy | Statins | fluorescein | Stroke | Cortex | Membrane permeability | Mass spectroscopy | Ischemia | Excitotoxicity | statins | Atorvastatin | Coenzyme A | Hydroxymethylglutaryl-CoA reductase | mevalonic acid | Seizures
Journal Article